Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 3.260
Filter
1.
BMC Oral Health ; 24(1): 551, 2024 May 11.
Article in English | MEDLINE | ID: mdl-38734599

ABSTRACT

BACKGROUND: Periodontal diseases may benefit more from topical treatments with nanoparticles rather than systemic treatments due to advantages such as higher stability and controlled release profile. This study investigated the preparation and characterization of thermosensitive gel formulations containing clindamycin-loaded niosomes and solid lipid nanoparticles (SLNs) loaded with fluconazole (FLZ), as well as their in vitro antibacterial and antifungal effects in the treatment of common microorganisms that cause periodontal diseases. METHODS: This study loaded niosomes and SLNs with clindamycin and FLZ, respectively, and assessed their loading efficiency, particle size, and zeta potential. The particles were characterized using a variety of methods such as differential scanning calorimetry (DSC), dynamic light scattering (DLS), and Transmission Electron Microscopy (TEM). Thermosensitive gels were formulated by combining these particles and their viscosity, gelation temperature, in-vitro release profile, as well as antibacterial and antifungal effects were evaluated. RESULTS: Both types of these nanoparticles were found to be spherical (TEM) with a mean particle size of 243.03 nm in niosomes and 171.97 nm in SLNs (DLS), and respective zeta potentials of -23.3 and -15. The loading rate was 98% in niosomes and 51% in SLNs. The release profiles of niosomal formulations were slower than those of the SLNs. Both formulations allowed the release of the drug by first-order kinetic. Additionally, the gel formulation presented a slower release of both drugs compared to niosomes and SLNs suspensions. CONCLUSION: Thermosensitive gels containing clindamycin-loaded niosomes and/or FLZ-SLNs were found to effectively fight the periodontitis-causing bacteria and fungi.


Subject(s)
Clindamycin , Fluconazole , Gels , Liposomes , Nanoparticles , Particle Size , Periodontal Diseases , Clindamycin/administration & dosage , Clindamycin/therapeutic use , Nanoparticles/chemistry , Fluconazole/administration & dosage , Fluconazole/pharmacology , Periodontal Diseases/drug therapy , Antifungal Agents/administration & dosage , Antifungal Agents/pharmacology , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacology , Microscopy, Electron, Transmission , Temperature , Calorimetry, Differential Scanning , Candida albicans/drug effects , Viscosity , Lipids/chemistry , Humans
2.
BMJ Case Rep ; 17(5)2024 May 13.
Article in English | MEDLINE | ID: mdl-38740445

ABSTRACT

A woman in her late 30s presented with sudden diminution of vision, redness and pain in the right eye (OD) of 10 days' duration. Best corrected visual acuity (BCVA) was 20/160 in OD and 20/20 in the left eye (OS). Anterior segment of OD showed keratic precipitates, flare 3+, cells 2+ and a festooned pupil. Vitreous haze and cells were seen in OD. Frosted branch angiitis (FBA) was seen in all quadrants in OD and old Toxoplasma scar was seen in both eyes. Serum toxoplasma immunoglobulin G (IgG) was positive and IgM negative, and PCR of an aqueous humour sample was negative for Toxoplasma She was diagnosed with toxoplasa retinochoroiditis in OD and treated with intravitreal clindamycin injections, oral anti-Toxoplasma antibiotics and steroids. Three months later, her BCVA in OD was 20/40 with resolving inflammation. She presented 2 months later with a new focus of retinochoroiditis without FBA and an old Toxoplasma scar.


Subject(s)
Chorioretinitis , Toxoplasma , Toxoplasmosis, Ocular , Humans , Female , Chorioretinitis/drug therapy , Chorioretinitis/diagnosis , Chorioretinitis/parasitology , Toxoplasmosis, Ocular/diagnosis , Toxoplasmosis, Ocular/drug therapy , Toxoplasmosis, Ocular/complications , Toxoplasma/isolation & purification , Adult , Multimodal Imaging , Vasculitis/drug therapy , Vasculitis/diagnosis , Vasculitis/complications , Visual Acuity , Clindamycin/therapeutic use , Clindamycin/administration & dosage , Tomography, Optical Coherence , Anti-Bacterial Agents/therapeutic use
3.
Int J Mol Sci ; 25(8)2024 Apr 16.
Article in English | MEDLINE | ID: mdl-38673971

ABSTRACT

Targeted therapy represents a real opportunity to improve the health and lives of patients. Developments in this field are confirmed by the fact that the global market for drug carriers was worth nearly $40 million in 2022. For this reason, materials engineering and the development of new drug carrier compositions for targeted therapy has become a key area of research in pharmaceutical drug delivery in recent years. Ceramics, polymers, and metals, as well as composites, are of great interest, as when they are appropriately processed or combined with each other, it is possible to obtain biomaterials for hard tissues, soft tissues, and skin applications. After appropriate modification, these materials can release the drug directly at the site requiring a therapeutic effect. This brief literature review characterizes routes of drug delivery into the body and discusses biomaterials from different groups, options for their modification with clindamycin, an antibiotic used for infections caused by aerobic and anaerobic Gram-positive bacteria, and different methods for the final processing of carriers. Examples of coating materials for skin wound healing, acne therapy, and bone tissue fillers are given. Furthermore, the reasons why the use of antibiotic therapy is crucial for a smooth and successful recovery and the risks of bacterial infections are explained. It was demonstrated that there is no single proven delivery scheme, and that the drug can be successfully released from different carriers depending on the destination.


Subject(s)
Anti-Bacterial Agents , Bacterial Infections , Biocompatible Materials , Clindamycin , Drug Delivery Systems , Humans , Clindamycin/therapeutic use , Clindamycin/administration & dosage , Biocompatible Materials/chemistry , Drug Delivery Systems/methods , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Bacterial Infections/prevention & control , Drug Carriers/chemistry , Animals
4.
BMJ Case Rep ; 17(4)2024 Apr 16.
Article in English | MEDLINE | ID: mdl-38627052

ABSTRACT

We report the case of a young, immunocompetent, non-pregnant woman diagnosed with acute abdomen 3 weeks after an ultrasound-guided transvaginal oocyte retrieval (TVOR). Peritoneal fluid, obtained during exploratory laparoscopy, yielded Mycoplasma hominis as the sole pathogen. The patient's symptoms and signs improved after 24-hour treatment with intravenous clindamycin, ampicillin and gentamycin. Complete resolution was achieved with oral doxycycline for 14 days.


Subject(s)
Mycoplasma Infections , Peritonitis , Female , Humans , Mycoplasma hominis , Oocyte Donation , Doxycycline , Clindamycin/therapeutic use , Peritonitis/drug therapy , Peritonitis/etiology , Mycoplasma Infections/diagnosis , Mycoplasma Infections/drug therapy
5.
Diagn Microbiol Infect Dis ; 109(3): 116266, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38643677

ABSTRACT

The aim of this study was to describe a case of a patient with ocular toxoplasmosis, which has resulted in Kyrieleis plaques formation (segmental periarteritis associated with severe inflammation) and later follow-up and alternative treatment due to documented allergy to sulfonamide. A 33-year-old Brazilian woman diagnosed with acute toxoplasmosis, initially treated with sulfonamide, developed a critical cutaneous rash. Cotrimoxazole was changed to clindamycin and pyrimethamine, and prednisone was started. The medication was maintained for 45 days. Four months later, she developed retinal lesions suggestive of toxoplasmosis with Kyrieleis plaques in the upper temporal vessels. Pyrimethamine, clindamycin, and prednisone were initiated until healing. She presented reactivation months later, and a suppressive treatment with pyrimethamine was instituted for one year. This is the first report to use the combination of clindamycin with pyrimethamine in the treatment and recurrence prophylaxis for OT in a documented allergy to sulfonamide.


Subject(s)
Clindamycin , Pyrimethamine , Sulfonamides , Toxoplasmosis, Ocular , Humans , Female , Adult , Pyrimethamine/therapeutic use , Pyrimethamine/adverse effects , Toxoplasmosis, Ocular/drug therapy , Sulfonamides/therapeutic use , Sulfonamides/adverse effects , Clindamycin/therapeutic use , Recurrence , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects , Drug Hypersensitivity/etiology , Brazil , Antiprotozoal Agents/therapeutic use , Antiprotozoal Agents/adverse effects , Treatment Outcome , Prednisone/therapeutic use
6.
Folia Microbiol (Praha) ; 69(3): 693-696, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38625660

ABSTRACT

Following the COVID-19 infection, the sternum dislocation and wound dehiscence resulted in an infection complicating the recovery of an immunosuppressed patient after bilateral lung transplantation. Anaerobic culture (96 h) of milky cloudy wound secretion resulted in the growth of pinpoint haemolytic colonies identified as Metamycoplasma hominis (formerly Mycoplasma hominis). The search for the endogenous source of the infection found the bacterium exclusively in the patient's sputum, making a possible link to donor lung M. hominis colonization. Unfortunately, the donor samples were no longer available. The wound infection was successfully treated with 17 days of clindamycin despite the continuous PCR detection of M. hominis in the sputum after the end of the treatment.


Subject(s)
Lung Transplantation , Mycoplasma Infections , Mycoplasma hominis , Surgical Wound Infection , Humans , Lung Transplantation/adverse effects , Surgical Wound Infection/microbiology , Surgical Wound Infection/drug therapy , Surgical Wound Infection/diagnosis , Mycoplasma hominis/genetics , Mycoplasma hominis/isolation & purification , Mycoplasma Infections/microbiology , Mycoplasma Infections/diagnosis , Mycoplasma Infections/drug therapy , Male , COVID-19/diagnosis , Anti-Bacterial Agents/therapeutic use , Sputum/microbiology , Middle Aged , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Immunocompromised Host , Clindamycin/therapeutic use
7.
Ann Clin Microbiol Antimicrob ; 23(1): 34, 2024 Apr 18.
Article in English | MEDLINE | ID: mdl-38637789

ABSTRACT

BACKGROUND: Chromobacterium is a genus of fourteen species with validly published names, most often found in soil and waters in tropical and subtropical regions around the world. The most well-known species of the genus, C. violaceum, occasionally causes clinically relevant infections; cases of soft tissue infections with septicemia and fatal outcomes have been described. CASE PRESENTATION: Here, we present a clinical case report of a 79-year-old man from Sweden with a soft-tissue infection and septicemia. The pathogen was identified as a strain of Chromobacterium species, but not C. violaceum. The patient was treated with clindamycin and ciprofloxacin and recovered well. CONCLUSIONS: This case report demonstrates the potential of Chromobacterium species as infectious agents in immunocompetent patients. It also indicates the existence of a novel species.


Subject(s)
Gram-Negative Bacterial Infections , Sepsis , Male , Humans , Aged , Chromobacterium , Sweden , Sepsis/diagnosis , Sepsis/drug therapy , Sepsis/microbiology , Ciprofloxacin/therapeutic use , Clindamycin/therapeutic use , Gram-Negative Bacterial Infections/microbiology
8.
Clin Lab ; 70(3)2024 Mar 01.
Article in English | MEDLINE | ID: mdl-38469790

ABSTRACT

BACKGROUND: This case involves a 28-year-old pregnant woman (39w+2) who was admitted to obstetrics due to abdominal tightness and bacteremia with Gardnerella vaginalis which developed after caesarean section and vaginal myomectomy. METHODS: A blood culture was performed, and the bacteria were identified through mass spectrometry. RESULTS: Mass spectrometry data indicated that the infection bacteria were Gardnerella vaginalis. The patient's temperature returned to normal after oral ampicillin in combination with clindamycin. CONCLUSIONS: Gardnerella vaginalis bacteremia is very rare in clinical practice, and the combination of ampicillin and clindamycin has a good therapeutic effect. This study may provide a reference for the diagnosis and treatment of Gardnerella vaginalis bacteremia.


Subject(s)
Bacteremia , Uterine Myomectomy , Vaginosis, Bacterial , Female , Pregnancy , Humans , Adult , Gardnerella vaginalis , Pregnant Women , Clindamycin/therapeutic use , Cesarean Section/adverse effects , Ampicillin/therapeutic use , Bacteremia/diagnosis , Bacteremia/drug therapy , Bacteremia/microbiology , Vaginosis, Bacterial/drug therapy , Vagina
9.
J Craniomaxillofac Surg ; 52(3): 355-362, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38368214

ABSTRACT

The aim of this study was to investigate the jawbone concentration of clindamycin (CLI) in patients with an osteonecrosis of the jaw (ONJ). Patients with medication-related ONJ (MRONJ) and osteoradionecrosis (ORN) with an antibiotic treatment with CLI were included. Plasma, vital and necrotic bone samples were collected. Plasma and jawbone samples were analyzed by liquid chromatography-tandem mass spectrometry. Patients with MRONJ exhibited a mean plasma CLI concentration of 9.6 µg/mL (SD ± 3.6 µg/mL) and mean concentrations of 2.3 µg/g CLI (SD ± 1.4 µg/g) and 2.1 µg/g CLI (SD ± 2.4 µg/g) in vital and necrotic bone samples, without statistical significance (p = 0.79). In patients with ORN, mean concentration in plasma was 12.0 µg/mL (SD ± 2.6 µg/mL), in vital bone 2.1 µg/g (SD ± 1.5 µg/g), and in necrotic bone 1.7 µg/g (SD ± 1.2 µg/g). Vital and necrotic bone concentrations did not differ significantly (p = 0.88). The results demonstrate that CLI concentrations are considerably lower than in plasma, but sufficient for most bacteria present in ONJ. Within the limitations of the study, it seems that CLI is a relevant alternative to other antibiotics in the treatment of ONJ because it reaches adequate concentrations in jawbone.


Subject(s)
Bisphosphonate-Associated Osteonecrosis of the Jaw , Bone Density Conservation Agents , Osteonecrosis , Osteoradionecrosis , Humans , Clindamycin/therapeutic use , Prospective Studies , Osteonecrosis/chemically induced , Osteoradionecrosis/etiology , Jaw , Bisphosphonate-Associated Osteonecrosis of the Jaw/etiology , Diphosphonates
10.
J Infect ; 88(3): 106104, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38360357

ABSTRACT

Streptococcus pyogenes (S. pyogenes) is a Gram-positive bacteria which causes a spectrum of diseases ranging from asymptomatic infection to life-threatening sepsis. Studies report up to 2000 times greater risk of invasive S. pyogenes disease in close contacts of index cases within 30-days of symptom onset. Despite this, there is variability in the management of asymptomatic carriage of S. pyogenes and those at risk of secondary cases of invasive S. pyogenes infection. OBJECTIVE: Our systematic review assessed the efficacy of different antibiotic regimens used for eradication of S. pyogenes from the pharynx in asymptomatic individuals. METHODS: We searched Pubmed, EMBASE (1974-), OVID Medline (1948-) and the Cochrane CENTRAL registry. We included randomised controlled trials (RCTs) with asymptomatic participants with >50% with pharyngeal cultures positive with S. pyogenes at baseline. Only studies with microbiological methods including culture (+/- polymerase chain reaction, PCR) were included. We included studies published in English. Each included study was assessed by two independent reviewers for data extraction and risk of bias. RESULTS: Of 1166 unique records identified, three RCTs were included in the review. Two of the three included RCTs found oral clindamycin for 10-days was the most efficacious regimen, compared to intramuscular benzathine penicillin G followed by 4 days of oral rifampicin, or monotherapy using benzathine penicillin, phenoxymethylpenicillin or erythromycin. Two RCTs were assessed as being at high risk of bias, with the third study demonstrating low/some risk of bias. CONCLUSIONS: Current available evidence for the optimal antibiotic in eradicating pharyngeal S. pyogenes carriage is limited. Future RCTs should include penicillin, first-generation cephalosporins, rifampicin, macrolides (such as azithromycin) and clindamycin.


Subject(s)
Anti-Bacterial Agents , Streptococcal Infections , Child , Adult , Humans , Anti-Bacterial Agents/therapeutic use , Streptococcus pyogenes , Clindamycin/therapeutic use , Penicillin G Benzathine , Pharynx/microbiology , Rifampin , Streptococcal Infections/drug therapy
12.
Clin Oral Investig ; 28(1): 100, 2024 Jan 17.
Article in English | MEDLINE | ID: mdl-38231453

ABSTRACT

OBJECTIVES: The study aims to overview German dentists' development of antibiotic and analgesic prescriptions from 2012 to 2021. MATERIALS AND METHODS: A longitudinal database analysis was performed based on the annual reports of the "Research Institute for Local Health Care Systems" (WIdO, Berlin). RESULTS: From 2012 until 2021, dental antibiotic prescriptions fell by 17.9%. In contrast, the dental proportion of antibiotic prescriptions compared to all antibiotic prescriptions in Germany increased from 9.1 to 13.6%. Aminopenicillins enhanced their share from 35.6 to 49.4%, while clindamycin prescriptions declined from 37.8 to 23.4%. The proportion of ibuprofen prescriptions significantly increased from 60.4% in 2012 to 79.0% in 2021. CONCLUSIONS: Since 2013, the most frequently prescribed antibiotic by German dentists has been amoxicillin reaching nearly half of all dental antibiotic prescriptions in 2021. Simultaneously, the proportion of clindamycin has steadily decreased, but the level is still high compared to international data. During the past decade, ibuprofen as a first-line analgesic in German dentistry was continuously gaining in importance. CLINICAL RELEVANCE: Aminopenicillins have the best risk-benefit balance in dentistry, but the use of antibiotics generally must be limited only to cases of severe infections or compromised patients. Pre-existing diseases or permanent medications should always be considered when choosing an analgesic.


Subject(s)
Anti-Bacterial Agents , Clindamycin , Humans , Anti-Bacterial Agents/therapeutic use , Clindamycin/therapeutic use , Ibuprofen/therapeutic use , Analgesics/therapeutic use , Germany , Penicillins , Prescriptions
13.
Am J Surg ; 232: 68-74, 2024 Jun.
Article in English | MEDLINE | ID: mdl-38199871

ABSTRACT

BACKGROUND: The clinical and financial impact of surgical site infection after ventral hernia repair is significant. Here we investigate the impact of dual antibiotic irrigation on SSI after VHR. METHODS: This was a multicenter, prospective randomized control trial of open retromuscular VHR with mesh. Patients were randomized to gentamicin â€‹+ â€‹clindamycin (G â€‹+ â€‹C) (n â€‹= â€‹125) vs saline (n â€‹= â€‹125) irrigation at time of mesh placement. Primary outcome was 30-day SSI. RESULTS: No significant difference was seen in SSI between control and antibiotic irrigation (9.91 vs 9.09 â€‹%; p â€‹= â€‹0.836). No differences were seen in secondary outcomes: SSO (11.71 vs 13.64 â€‹%; p â€‹= â€‹0.667); 90-day SSO (11.1 vs 13.9 â€‹%; p â€‹= â€‹0.603); 90-day SSI (6.9 vs 3.8 â€‹%; p â€‹= â€‹0.389); SSIPI (7.21 vs 7.27 â€‹%, p â€‹= â€‹0.985); SSOPI (3.6 vs 3.64 â€‹%; p â€‹= â€‹0.990); 30-day readmission (9.91 vs 6.36 â€‹%; p â€‹= â€‹0.335); reoperation (5.41 vs 0.91 â€‹%; p â€‹= â€‹0.056). CONCLUSION: Dual antibiotic irrigation with G â€‹+ â€‹C did not reduce the risk of surgical site infection during open retromuscular ventral hernia repair.


Subject(s)
Anti-Bacterial Agents , Gentamicins , Hernia, Ventral , Herniorrhaphy , Surgical Wound Infection , Therapeutic Irrigation , Humans , Hernia, Ventral/surgery , Surgical Wound Infection/prevention & control , Surgical Wound Infection/epidemiology , Male , Female , Middle Aged , Prospective Studies , Herniorrhaphy/adverse effects , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Gentamicins/administration & dosage , Gentamicins/therapeutic use , Incidence , Therapeutic Irrigation/methods , Clindamycin/therapeutic use , Clindamycin/administration & dosage , Aged , Surgical Mesh , Treatment Outcome , Adult
14.
Photodiagnosis Photodyn Ther ; 45: 103928, 2024 Feb.
Article in English | MEDLINE | ID: mdl-38070633

ABSTRACT

BACKGROUND: The treatment of acne vulgaris is often challenging due to the antibiotic resistance frequently observed in Cutibacterium acnes (C.acnes), a prevalent bacterium linked to this condition. OBJECTIVE: The objective of this research was to examine the impact of curcumin photodynamic therapy (PDT) on the survival of C.acnes and activity of biofilms produced by this microorganism. METHODS: Following the Clinical and Laboratory Standards Institute (CLSI) guidelines, we assessed the drug sensitivity of 25 clinical C.acnes strains to five antibiotics (erythromycin, clindamycin, tetracycline, doxycycline, minocycline) and curcumin by implementing the broth microdilution technique. In addition, we established C.acnes biofilms in a laboratory setting and subjected them to curcumin-PDT(curcumin combined with blue light of 180 J/cm2). Afterwards, we evaluated their viability using the XTT assay and observed them using confocal laser scanning microscopy. RESULTS: The result revealed varying resistance rates among the tested antibiotics and curcumin, with erythromycin, clindamycin, tetracycline, doxycycline, minocycline, and curcumin exhibiting resistance rates of 72 %, 44 %, 36 %, 28 %, 0 %, and 100 %, respectively. In the curcumin-PDT inhibition tests against four representative antibiotic-resistant strains, it was found that the survival rate of all strains of planktonic C. acnes was reduced, and the higher the concentration of curcumin, the lower the survival rate. Furthermore, in the biofilm inhibition tests, the vitality and three-dimensional structure of the biofilms were disrupted, and the inhibitory effect became more significant with higher concentrations of curcumin. CONCLUSION: The results emphasize the possibility of using curcumin PDT as an alternative approach for the treatment of C.acnes, especially in instances of antibiotic-resistant variations and infections related to biofilms.


Subject(s)
Acne Vulgaris , Curcumin , Photochemotherapy , Humans , Clindamycin/pharmacology , Clindamycin/therapeutic use , Doxycycline/pharmacology , Doxycycline/therapeutic use , Curcumin/pharmacology , Curcumin/therapeutic use , Minocycline/pharmacology , Minocycline/therapeutic use , Microbial Sensitivity Tests , Photosensitizing Agents/pharmacology , Photosensitizing Agents/therapeutic use , Photochemotherapy/methods , Acne Vulgaris/drug therapy , Anti-Bacterial Agents/therapeutic use , Erythromycin/pharmacology , Erythromycin/therapeutic use , Tetracycline/pharmacology , Tetracycline/therapeutic use , Biofilms , Propionibacterium acnes
15.
Int J Oral Maxillofac Surg ; 53(3): 251-257, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37758642

ABSTRACT

This retrospective analysis was performed to investigate whether clindamycin remains the preferred antibiotic for penicillin-allergic patients with odontogenic infections. The medical records of 311 patients admitted to the study department with odontogenic infections between 2018 and 2022 and treated with either intravenous amoxicillin-clavulanic acid (Augmentin) or intravenous clindamycin were analyzed. The Augmentin-treated group included 268 patients (86.2%) and the clindamycin-treated group included 43 patients (13.8%). Severity parameters did not differ significantly between the two groups, except for a higher prevalence of abscesses in the clindamycin-treated group (58.1% vs 41.0% in the Augmentin-treated group; P = 0.035). The clindamycin-treated group required a longer duration of intravenous antibiotics (P = 0.001) and had a higher rate of treatment failure (14.0% vs 2.2%; P = 0.002) when compared to the Augmentin-treated group, with a seven-fold increased risk of treatment failure. Moreover, significantly more isolated organisms in the clindamycin-treated group were resistant to clindamycin (P = 0.015); these were all Streptococcus anginosus group. Given the higher risk of treatment failure with clindamycin, it is necessary to choose the antibiotic treatment for penicillin-allergic patients carefully. A detailed history and allergy testing followed by combination therapy is recommended, especially in severe cases.


Subject(s)
Clindamycin , Penicillins , Humans , Penicillins/therapeutic use , Clindamycin/therapeutic use , Amoxicillin-Potassium Clavulanate Combination/therapeutic use , Retrospective Studies , Anti-Bacterial Agents/therapeutic use
16.
Br J Dermatol ; 190(3): 382-391, 2024 Feb 16.
Article in English | MEDLINE | ID: mdl-37823414

ABSTRACT

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, painful disease affecting flexures and other skin regions, producing nodules, abscesses and skin tunnels. Laser treatment targeting hair follicles and deroofing of skin tunnels are standard HS interventions in some countries but are rarely offered in the UK. OBJECTIVES: To describe current UK HS management pathways and influencing factors to inform the design of future randomized controlled trials (RCTs). METHODS: THESEUS was a nonrandomized 12-month prospective cohort study set in 10 UK hospitals offering five interventions: oral doxycycline 200 mg daily; oral clindamycin and rifampicin both 300 mg twice daily for 10 weeks, extended for longer in some cases; laser treatment targeting hair follicles; deroofing; and conventional surgery. The primary outcome was the combination of clinician-assessed eligibility and participant hypothetical willingness to receive each intervention. The secondary outcomes were the proportion of participants selecting each intervention as their final treatment option; the proportion who switch treatments; treatment fidelity; and attrition rates. THESEUS was prospectively registered on the ISRCTN registry: ISRCTN69985145. RESULTS: The recruitment target of 150 participants was met after 18 months, in July 2021, with two pauses due to the COVID-19 pandemic. Baseline demographics reflected the HS secondary care population: average age 36 years, 81% female, 20% non-White, 64% current or ex-smokers, 86% body mass index ≥ 25, 68% with moderate disease, 19% with severe disease and 13% with mild disease. Laser was the intervention with the highest proportion (69%) of participants eligible and willing to receive treatment, then deroofing (58%), conventional surgery (54%), clindamycin and rifampicin (44%), and doxycycline (37%). Laser was ranked first choice by the greatest proportion of participants (41%). Attrition rates were 11% and 17% after 3 and 6 months, respectively. Concordance with doxycycline was 52% after 3 months due to lack of efficacy, participant choice and adverse effects. Delays with procedural interventions were common, with only 43% and 26% of participants starting laser and deroofing, respectively, after 3 months. Uptake of conventional surgery was too small to characterize the intervention. Switching treatment was uncommon and there were no serious adverse events. CONCLUSIONS: THESEUS has established laser treatment and deroofing for HS in the UK and demonstrated their popularity with patients and clinicians for future RCTs.


Subject(s)
Clindamycin , Hidradenitis Suppurativa , Female , Humans , Adult , Male , Clindamycin/therapeutic use , Rifampin , Hidradenitis Suppurativa/surgery , Doxycycline/therapeutic use , Cohort Studies
17.
J Matern Fetal Neonatal Med ; 37(1): 2295805, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38124302

ABSTRACT

OBJECTIVE: This study was aimed to investigate the serotypes, antibiotic susceptibilities, and multi-locus sequence type (MLST) profiles of group B Streptococcus (GBS) in the Beijing area. METHODS: Lower vaginal and rectal swabs were obtained from pregnant women of 35-37 gestational weeks (GWs) who attended the Beijing Obstetrics and Gynecology Hospital. All GBS isolates were identified with Gram staining, catalase reaction assays, and CAMP tests, followed by antibiotic susceptibility testing, serotype identification, multilocus sequence typing and erythromycin resistance gene analysis (ermB and mefE). RESULTS: From July 2020 to June 2022, 311 (5.17%) of 6012 pregnant women that were screened for GBS colonization were detected positive. Of the eight serotypes identified (III, Ia, Ib, IV, II, VIII, V, and NT), serotypes III (43.09%), Ia (34.08%) and Ib (17.04%) were the predominant species. In the antimicrobial susceptibility experiments, the resistant rates measured for erythromycin, clindamycin, levofloxacin, and tetracycline were 76.21%, 63.99%, 50.80%, and 81.03%, respectively, and 7.6% of GBS isolates showed inducible clindamycin in resistance (D-test phenotype). Meanwhile, the multilocus sequence typing analysis showed that sequence type 19 (ST19) (30.34%) and ST10 (18.62%) were the dominant sequence types. Among the 237 erythromycin-resistant isolates, 176 harbored ermB (128, 54.00%) or mefE (48, 20.30%) gene alone. CONCLUSION: The infection rates, serotypes or MSLT distribution, and antimicrobial resistance of GBS in Beijing area were investigated, which may be applied in analyses of the epidemiological characteristics of GBS. This contributes to the basic knowledge required for successful GBS vaccine development suited for disease prevention and treatment in China, as well as the implementation of effective clinical antimicrobials.


Subject(s)
Anti-Bacterial Agents , Streptococcal Infections , Female , Humans , Pregnancy , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Serogroup , Pregnant Women , Clindamycin/pharmacology , Clindamycin/therapeutic use , Streptococcal Infections/drug therapy , Streptococcal Infections/epidemiology , Multilocus Sequence Typing , Drug Resistance, Bacterial/genetics , Erythromycin/pharmacology , Streptococcus agalactiae/genetics , China/epidemiology , Microbial Sensitivity Tests
18.
J Infect Chemother ; 30(7): 651-654, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38097041

ABSTRACT

Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) is a global concern, primarily as a cause of skin and soft tissue infections, particularly in young people. Here, we describe a case of unilateral multiple lymphadenitis caused by the CA-MRSA sequence type (ST) 834 strain. A previously healthy 15-year-old girl was referred to our hospital with fever and swollen lymph nodes in the right axillary, cubital, and groin regions. Imaging examinations revealed enlargement of the lymph nodes in these areas but no swelling in any other lymph nodes. The patient had self-destructive lymph nodes in her groin. MRSA was detected in all swollen lymph node samples. Antimicrobial susceptibility tests showed that MRSA was susceptible to clindamycin and levofloxacin, leading to the suspicion of CA-MRSA. Genetic analysis revealed that all strains were ST834 and carried the staphylococcal cassette chromosome mec IV and the toxic shock syndrome toxin-1 gene but not the Panton-Valentine leukocidin gene. The patient was treated with linezolid followed by oral clindamycin. This was a rare case of unilateral multiple lymphadenitis caused by ST834 CA-MRSA. Although ST834 strains are rarely reported, lymphadenitis has been frequently reported and is considered more likely to cause lymphadenitis than other CA-MRSA strains.


Subject(s)
Anti-Bacterial Agents , Community-Acquired Infections , Lymphadenitis , Methicillin-Resistant Staphylococcus aureus , Staphylococcal Infections , Humans , Female , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Methicillin-Resistant Staphylococcus aureus/genetics , Methicillin-Resistant Staphylococcus aureus/drug effects , Adolescent , Staphylococcal Infections/microbiology , Staphylococcal Infections/drug therapy , Staphylococcal Infections/diagnosis , Lymphadenitis/microbiology , Lymphadenitis/drug therapy , Community-Acquired Infections/microbiology , Community-Acquired Infections/drug therapy , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Clindamycin/therapeutic use , Microbial Sensitivity Tests , Linezolid/therapeutic use
19.
J Eur Acad Dermatol Venereol ; 38(5): 904-909, 2024 May.
Article in English | MEDLINE | ID: mdl-38112226

ABSTRACT

BACKGROUND: Adalimumab monotherapy for hidradenitis suppurativa (HS) is often insufficient with a maximum clinical efficacy of 60% in Hidradenitis Suppurativa Clinical Response (HiSCR) and limited effect on draining tunnels. Data suggest that adalimumab therapy could be improved by concomitant antibiotics. OBJECTIVE: To compare the clinical effectiveness of adalimumab with clindamycin and rifampicin versus adalimumab monotherapy after 12 weeks. METHODS: This retrospective study included patients who started adalimumab with additional clindamycin and rifampicin and patients treated with adalimumab monotherapy, matched on sex and refined Hurley score. The primary outcome measure was the difference in change in the International Hidradenitis Suppurativa Severity Score System (IHS4) at 12 weeks. RESULTS: In total, 62 patients were included in the combination therapy group (n = 31) and adalimumab monotherapy group (n = 31), showing comparable IHS4 scores; 32.5 versus 29, p = 0.87 at baseline respectively. The combination therapy demonstrated greater clinical effectiveness expressed in median IHS4 improvement (-20 vs. -9, p < 0.001), IHS4-55 (74% vs. 36%, p = 0.002), median draining tunnel reduction (-4 vs. -2, p < 0.001) and pain response (47% vs. 27%, p = 0.02). CONCLUSION: Adalimumab initiated with clindamycin and rifampicin shows greater clinical effectiveness than adalimumab monotherapy. An important difference in effect was observed in the decrease of draining tunnels, addressing a serious limitation of adalimumab monotherapy.


Subject(s)
Adalimumab , Clindamycin , Drug Therapy, Combination , Hidradenitis Suppurativa , Rifampin , Humans , Hidradenitis Suppurativa/drug therapy , Adalimumab/therapeutic use , Adalimumab/administration & dosage , Rifampin/therapeutic use , Rifampin/administration & dosage , Clindamycin/therapeutic use , Clindamycin/administration & dosage , Retrospective Studies , Female , Male , Adult , Middle Aged , Severity of Illness Index , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/administration & dosage , Treatment Outcome
20.
Article in English | MEDLINE | ID: mdl-37817335

ABSTRACT

Group B streptococcus (GBS) is a significant cause of perinatal morbidity and mortality; prophylactic antibiotics in the obstetric population can mitigate the risk of neonatal infection. The antibiotic of choice is penicillin; however, in women who have a penicillin hypersensitivity, clindamycin is the preferred agent. Worldwide resistance to clindamycin is rising in GBS isolates. In the Top End of the Northern Territory of Australia, we reviewed 113 GBS isolates in 2023. These GBS isolates revealed a 30% resistance to clindamycin. This rate has considerably increased since the Australia-wide survey published in 2011 where GBS resistance to clindamycin was quoted at 4.2%. As a result of this study, we are advocating for a change in practice in patients with known GBS resistance with penicillin hypersensitivity.


Subject(s)
Anti-Bacterial Agents , Clindamycin , Drug Resistance, Bacterial , Streptococcal Infections , Streptococcus agalactiae , Humans , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Clindamycin/pharmacology , Clindamycin/therapeutic use , Northern Territory/epidemiology , Streptococcus agalactiae/drug effects , Streptococcal Infections/drug therapy , Streptococcal Infections/epidemiology , Streptococcal Infections/microbiology
SELECTION OF CITATIONS
SEARCH DETAIL
...